3SBio gears up for drugs battle with $400 million equity move
After grabbing the spotlight this year with a big licensing deal, the Chinese drug developer is now raising extra funds for R&D and shedding a non-core subsidiary Key takeaways: 3SBio…
Ming Yu seeks a share of the drug sector limelight
Led by a former research chief at drugs giant Hengrui, the Chinese biotech can boast solid credentials and big-name backers as it positions for a Hong Kong IPO Key Takeaways:…
Neglected Burning Rock charms investors with high margins, narrowing losses
The cancer diagnostics company’s revenue rose slightly in the third quarter, as its gross margin rose by nearly 4 percentage points Key Takeaways: Burning Rock’s revenue rose 2.3% in the…
CSPC feels the pain from sweeping cuts in drug prices
The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…
Genuine Biotech takes third shot at IPO as financial pressures mount
Demand for the company’s core product has long since faded, and sales for the product took an additional hit after the termination of a distribution partnership with Fosun Pharma Key…
China’s corporate pivots: Alibaba’s food delivery gambit and WuXi AppTec’s geopolitical hedge
Alibaba will retire the Ele.me takeout dining brand and merge it with its newer Taobao Instant Commerce. What's driving the move? And WuXi AppTec is the latest Chinese major to jump on the Middle Eastern bandwagon, with plans to potentially open a new center in Saudi Arabia. Why are a growing number of Chinese companies taking the Middle Eastern plunge?
BenQ BM takes pulse of hot Hong Kong market with new IPO bid
The private hospital operator has filed again for a Hong Kong listing, offering uninspired financials to investors after two unsuccessful attempts since last year Key Takeaways: Private hospital operator BenQ…
Recent Articles
RELATED ARTICLES
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK -
RemeGen’s $4.2 billion licensing deal falls flat with investors
9995.HK688331.SHG
-
So big but so what? Innovent’s license deal fails to excite investors
1801.HK
-
Zai Lab under pressure over clinical results and rival drugs
9688.HKZLAB.US
-
CSPC feels the pain from sweeping cuts in drug prices
1093.HK
-
Akeso shares take a hit despite surging sales of cancer drugs
9926.HK
-
BRIEF: Ubtech to raise $400 million in share placement at 11.4% discount
9880.HK
